The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 386-396

  Lahiri, Debomoy K ^a   Chen, DeMao ^a   Maloney, Bryan ^a   Holloway, Harold W ^b   Yu, Qian Sheng ^b   Utsuki, Tada ^b,c   Giordano, Tony ^c   Sambamurti, Kumar ^d   Greig, Nigel H ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; BETA SECRETASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE; PHENSERINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL CULTURE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; ENANTIOMER; EX VIVO STUDY; HEMISPHERE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MEDICAL RESEARCH; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, INBRED C57BL; PHYSOSTIGMINE; RNA, MESSENGER; STEREOISOMERISM;

EID: 33845905829     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.112102     Document Type: Article

References (44)

1. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, and Zawia NH (2005) The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25:823-829.
2. Cairns NJ, Lee VM, and Trojanowski JQ (2004) The cytoskeleton in neurodegenerative diseases. J Pathol 204:438-449.
3. Giacobini E (2003) Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 18:S1-5.
4. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, and Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422.
5. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, and Lahiri DK (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-{alpha} inhibitors, and GLP-1 receptor agonists. Ann NY Acad Sci 1035:290-315.
6. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, and Lahiri DK (2005) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2:281-290.
7. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, and Wallace WC (1997) Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res 46:161-168.
8. Holcik M and Sonenberg N (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6:318-327.
9. Holsinger RM, McLean CA, Beyreuther K, Masters CL, and Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51:783-786.
10. Kann E and Dever TE (2004) Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci 5:931-942.
11. Klegeris A and McGeer PL (2005) Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2:355-365.
12. LaFerla FM and Oddo S (2005) Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11:170-176.
13. Lahiri DK, Alley GM, Chen D, and Greig NH (2006) Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease. Neuromol Med, in press.
14. Lahiri DK, Chen D, Ge YW, Bondy SC, and Sharman EH (2004) Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res 36:224-231.
15. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH, and Rogers JT (2003a) Role of cytokines in the gene expression of amyloid beta-protein precursor: Identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimers Dis 5:81-90.
16. Lahiri DK, Farlow MR, and Sambamurti K (1998) The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol Brain Res 62:131-140.
17. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, and Schneider LS (2003b) A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 4:97-112.
18. Lahiri DK, Lewis S, and Farlow MR (1994) Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 37:777-787.
19. Y, Zhou W, Tong Y, He G, and Song W (2006) Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J 20:285-292.
20. Lleo A, Greenberg SM, and Growdon JH (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57:513-533.
21. Maloney B, Ge YW, Greig N, and Lahiri DK (2004) Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. FASEB J 18:1288-1290.
22. Mbella EG, Bertrand S, Huez G, and Octave JN (2000) A GG nucleotide sequence of the 3′ untranslated region of amyloid precursor protein mRNA plays a key role in the regulation of translation and the binding of proteins. Mol Cell Biol 20:4572-4579.
23. Morgan D and Gitter BD (2004) Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol Aging 25:605-608.
24. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, and Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452.
25. Pakaski M and Kasa P (2003) Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Targets CNS Neurol Disord 2:163-171.
26. Pickering BM and Willis AE (2005) The implications of structured 5′ untranslated regions on translation and disease. Semin Cell Dev Biol 16:39-47.
27. Racchi M, Mazzucchelli M, Porrello E, Lanni C, and Govoni S (2004) Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 50:441-451.
28. Rogers GW Jr, Edelman GM, and Mauro VP (2004) Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci USA 101:2794-2799.
29. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, and Nilsson LN (1999) Translation of the Alzheimer amyloid precursor protein mRNA is upregulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 274:6421-6431.
30. Sambamurti K, Greig NH, and Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol Med 1:1-31.
31. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, and Greig NH (2006) A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3:81-90.
32. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, et al. (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103:443-448.
33. Selkoe DJ (2005) Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62:192-195.
34. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, and Greig NH (2001) Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98:7605-7610.
35. Steiner H (2004) Uncovering gamma-secretase. Curr Alzheimer Res 1:175-181.
36. Sutton MA and Schuman EM (2005) Local translational control in dendrites and its role in long-term synaptic plasticity. J Neurobiol 64:116-131.
37. Utsuki T, Yu Q-S, Davidson D, Powers G, Chen D, Holloway HW, Sambamurti K, Lahiri DK, Greig NH, and Giordano T (2006) Identification of novel small molecule inhibitors of APP protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther 318:855-862.
38. Vardy ER, Catto AJ, and Hooper NM (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11:464-472.
39. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, and Rogers JT (2004) The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann NY Acad Sci 1035:34-48.
40. Wallace WC, Bragin V, Robakis NK, Sambamurti K, VanderPutten D, Merril CR, Davis KL, Santucci AC, and Haroutunian V (1991) Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res 10:173-178.
41. Wallace WC, Lieberburg I, Schenk D, Vigo-Pelfrey C, Davis KL, and Haroutunian V (1995) Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J Neurosci 15:4896-4905.
42. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, and Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (Lond) 416:535-539.
43. Wolfe MS (2006) The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45:7931-7939.
44. Yu QS, Pei XF, Holloway HW, Greig NH, and Brossi A (1997) Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. J Med Chem 40:2895-2901.